Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN).

In this article we will dive into REGENERON PHARMACEUTICALS (NASDAQ:REGN) as a possible candidate for quality investing. Investors should always do their own research, but we noticed REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Looking into the quality metrics of REGENERON PHARMACEUTICALS

• The 5-year revenue growth of REGENERON PHARMACEUTICALS has been remarkable, with 15.7% increase. This showcases the company's strong performance in driving revenue growth and indicates its competitiveness within the market.
• REGENERON PHARMACEUTICALS demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 21.98% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
• With a Debt/Free Cash Flow Ratio of 0.62, REGENERON PHARMACEUTICALS exhibits solid financial health and responsible debt management practices. This ratio indicates the company's ability to generate ample free cash flow to meet its debt obligations and pursue growth opportunities.
• With a favorable Profit Quality (5-year) ratio of 76.98%, REGENERON PHARMACEUTICALS showcases its ability to consistently deliver high-quality profits. This metric signifies the company's financial strength and its capacity to generate sustainable earnings over an extended period.
• The 5-year EBIT growth of REGENERON PHARMACEUTICALS has been remarkable, with 19.15% increase. This demonstrates the company's ability to improve its operational efficiency and indicates its competitiveness within the market.
• With EBIT 5-year growth outpacing its Revenue 5-year growth, REGENERON PHARMACEUTICALS showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

How does the complete fundamental picture look for NASDAQ:REGN?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 609 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN is not valued too expensively and it also shows a decent growth rate.

Our latest full fundamental report of REGN contains the most current fundamental analsysis.

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.